Controlled drug release system of light-responsive nanocarrier, preparation and use thereof
Through the self-assembled photoresponsive nanocarrier of three-legged small molecules, the dicyanocoumarin group triggered by green light is solved, and the existing photoresponsive system is complex structure and poor light penetration is achieved, achieving fast and safe drugs Delivery and controlled release, successfully used in the treatment of retinoblastoma.
Patent Information
- Application Number
- CN202180029535.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-04-24
- Filing Date
- 2021-03-17
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2041-03-17
AI Technical Summary
The existing photoresponsive nanocarrier systems are complex in construction, the controlled release process is not fast enough, and poor light penetration and phototoxicity limit their conversion in biomedical applications, especially for ocular drug delivery systems, lacking effective greens. Light trigger system.
A photoresponsive nanocarrier self-assembled by three-legged small molecules is designed. The dicyano-modified coumarin is used as a green light cleavable group, which can quickly respond to 505nm green light, reduce phototoxicity, and pass self-assembly Nanoparticles are formed to encapsulate hydrophobic drugs and achieve rapid drug release.
Achieve rapid and controllable drug release, improve light penetration depth and safety, and successfully deliver the drug to the posterior segment of the eye for the treatment of retinoblastoma, demonstrating the potential of intravenous administration and reducing vitreous Pain and side effects of intravenous injection.
Smart Images

Figure BDA0003897639000000021 
Figure BDA0003897639000000041 
Figure BDA0003897639000000042
Abstract
Description
1. Technical Field
[0001] The present invention discloses a controlled drug release system of a light-responsive nanocarrier, a method for preparing the nanocarrier, and a method for treating a disease using the nanocarrier. 2. Background technology
[0002] Many photoresponsive nanocarriers that can achieve light-controlled drug release have been reported. However, most of them are constructed of polymer materials and can only be triggered by UV light, which is completely different from our design. Professor Adah Almutairi reported a UV light-degradable polymer that allows drug release triggered by light. However, this system requires intravitreal administration for ocular drug delivery. In addition, there is no light-triggered drug release system on the market.
[0003] The construction of conventional photoresponsive systems is usually complicated because the photoresponsive groups are integrated into the system (mainly polymers), which requires multiple steps to synthesize. Due to the stability of the polymer backbone, the controlled release process is not fast enough. Photoresponsive drug delivery systems usually have poor light penetration and phototoxicity limitations, which restrict their translational applications. 3. Summary of the invention
[0004] To address these issues, we designed small clathrin-like (three-legged) molecules that can self-assemble into nanoparticles. The synthesis of these molecules is relatively simple, and nanoparticles can be conveniently constructed by one-step self-assembly in water. In addition, the release of the encapsulated cargo upon light triggering can be rapid because the assembly of small molecules can be easily dissociated upon photocleavage of the molecules. For the light penetration issue, we used dicyano-modified coumarins, a photocleavable group that responds to green light, instead of traditional coumarins that absorb UV light. Green light has a deeper tissue penetration depth than UV light. As a proof-of-concept study, drug-loaded nanocarriers were phototriggered to degrade and successfully delivered the drug to the posterior segment of the eye. This strategy also eliminates phototoxicity because green light is less harmful to normal tissues such as the retina than UV or blue light.
[0005] Photoresponsive drug delivery systems (PDDS) have been confirmed to be suitable for spatiotemporally controlled drug release. However, poor light penetration and unreliable drug release processes remain challenging for biomedical applications. Here, we developed novel photoresponsive nanocarriers self-assembled from three-legged small molecules. Compared with other photoresponsive drug delivery systems, this nanocarrier can rapidly respond to irradiation with 505nm green light, which has a deeper tissue penetration depth and lower phototoxicity than the commonly used UV light. In addition, the unique three-legged molecules can spontaneously self-assemble into nanocarriers and encapsulate hydrophobic drugs in aqueous solution. As a potential application, we encapsulated doxorubicin (DOX) in the nanocarriers and successfully delivered it to the posterior segment of the eye for the treatment of retinoblastoma. This is the first example of photoresponsive nanoparticles self-assembled from three-legged molecules. To the best of our knowledge, this is also the first example of light-triggered drug release in the eye from an intravenously administered photoresponsive drug delivery system.
[0006] Provided herein is a drug delivery system comprising: a nanocarrier and a pharmaceutical agent, wherein the nanocarrier comprises a photoresponsive three-legged molecule capable of self-assembling into nanoparticles.
[0007] Provided herein is a drug delivery system comprising: a nanocarrier and a pharmaceutical agent, wherein the nanocarrier comprises formula (X) 3 -TAEA, wherein X is a photoresponsive molecule capable of self-assembly into nanoparticles.
[0008] Provided herein is a drug delivery system comprising: a nanocarrier and a pharmaceutical agent, wherein the nanocarrier comprises (DEAdcCM)3-TAEA (DTAEA) having the following formula:
[0009]
[0010] In some embodiments, the nanocarriers have a size of about 10-300 nm.
[0011] In some embodiments, the nanocarriers have a polydispersity (PDI) of about 0.4 to 0.
[0012] In some embodiments, the nanocarriers have a size of about 90 nm and a polydispersity (PDI) of about 0.086.
[0013] In some embodiments, the nanocarrier has a zeta potential of about -10 mV to -40 mV.
[0014] In some embodiments, the nanocarrier has a zeta potential of about -27 mV.
[0015] In some embodiments, the nanocarriers are photoresponsive.
[0016] In some embodiments, the pharmaceutical agent is a hydrophobic drug or an imaging dye.
[0017] In some embodiments, the agent is used for imaging or treatment of ocular diseases (e.g., retinoblastoma, age-related macular degeneration, etc.) and other diseases where light can somehow reach its target (e.g., using fiber optics) (e.g., melanoma, subcutaneous tumors, esophageal cancer, gastric cancer, etc.).
[0018] In some embodiments, the pharmaceutical agent is doxorubicin (DOX), paclitaxel (PTX), capecitabine, or the like.
[0019] Provided herein are methods of treating a disease in a subject, comprising the steps of administering a delivery system disclosed herein to the subject, and irradiating the subject with light.
[0020] In some embodiments, the light is delivered by an LED light source, a lamp, a laser source, or an optical fiber.
[0021] In some embodiments, the nanocarriers are triggered by green light irradiation.
[0022] In some embodiments, the nanocarriers are triggered by irradiation with blue light, red light, or near infrared light (NIR).
[0023] In some embodiments, the light has a wavelength of 600-1200 nm.
[0024] In some embodiments, the light has a wavelength of 400-600 nm.
[0025] In some embodiments, the light is 505 nm in wavelength and 50 mW / cm 2 Green LED light lasts for 5 minutes.
[0026] In some embodiments, the delivery system is administered intravenously.
[0027] In some embodiments, the subject is irradiated 0-4 h after administration of the delivery system.
[0028] In some embodiments, the disease is skin cancer, esophageal cancer, stomach cancer, eye disease, retinoblastoma, and other diseases where light can reach its target.
[0029] Provided herein are methods of making the systems disclosed herein, wherein DTAEA is assembled in the presence of DSPE-mPEG to form a nanocarrier.
[0030] Provided herein is a method for synthesizing (DEAdcCM)3-TAEA (DTAEA), the method comprising the following steps:
[0031]
[0032] The present invention provides a method for synthesizing (DEAdcCM)3-TAEA (DTAEA), the method comprising the following steps: (i) modifying a 7-(diethylamino)-4-(hydroxymethyl)-coumarin (DEACM) photocage having the following structure with malononitrile:
[0033]
[0034] To form dicyanocoumarin (DEAdcCM) having the following structure:
[0035]
[0036] (ii) DEAdcCM was attached to the TAEA amino group via a nitrochloroformate-mediated reaction of the hydroxyl and amino groups to form DTAEA.
[0037] 4. Brief description of the accompanying drawings
[0038] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0039] Scheme 1 - Self-assembly, photodegradation and drug release of Dox-loaded (DEAdcCM)3-TAEA (DTAEA) nanocarriers. A proposed pathway for drug accumulation in the eye is also presented.
[0040] Figure 1 Synthetic route of DEAdcCM-TAEA (DTAEA).
[0041] Figure 2 DTAEA molecule 1 H-NMR spectrum.
[0042] Figure 3 ESI-MS spectrum of DTAEA molecule.
[0043] Figure 4 Structures and UV-visible spectra of two photocleavable groups: coumarin (DEACM) and dicyanocoumarin (DEAdcCM).
[0044] Figure 5 Self-assembly of DTAEA nanoparticles. (A) DTAEA self-assembly scheme. (B) TEM image of DTAEA nanoparticles. (C) Size and (D) zeta potential of DTAEA nanoparticles, peaking at 89.46 nm and -25.1 mV, respectively. (E) Changes in size and polydispersity of DTAEA nanoparticles in PBS at 37 °C over 24 h.
[0045] Figure 6 Photolysis of DTAEA. (A) Proposed scheme of the photolysis mechanism. (B) Photolysis rate of DTAEA in 1:1 ACN / H2O (v / v) solution and DTAEA nanoparticles in water. (C) Photolysis of DTAEA in PBS before and after irradiation (Mightex LED light source, 505 nm, 50 mW / cm 2 )HPLC curve of DTAEA nanoparticles.
[0046] Figure 7 Characterization of DOX-loaded DTNPs (DOX / DTNPs). (A) UV-visible spectra of DTNPs, DOX / DTNPs, and DOX. (B) Encapsulation efficiency and loading capacity of DTNPs with different feed ratios (DOX / DTAEA, w / w). (C) Size and zeta potential of DTNPs and DOX / DTNPs.
[0047] Figure 8 Light irradiation (505nm, 50mW / cm 2 TEM images of DTNPs before and after 5 min).
[0048] Fig. 9 Light-triggered release curve of DOX from DOX / DTNP. The nanoparticles were irradiated for 1 min and then dialyzed for 10 min. The released drug molecules were detected by HPLC.
[0049] Fig.10 Light-triggered DOX uptake in HUVEC cells. Representative fluorescence microscopy images of HUVEC cells incubated with various agents.
[0050] Fig.11 Light-triggered DOX uptake in WERI-Rb-1 cells. (A) Representative confocal microscopy images of WERI-Rb-1 cells. (B) Representative flow cytometry data of DEAdcCM fluorescence in WERI-Rb-1 cells incubated with DOX / DTNPs and treated with or without irradiation. (C) Representative flow cytometry data of DOX fluorescence in WERI-Rb-1 cells incubated with DOX / DTNPs and treated with or without irradiation. (D) Quantification of flow cytometry data (average of four median values of fluorescence intensity).
[0051] Fig.12 Cytotoxicity of DTNP and light irradiation on WERI-Rb-1 cells. (A) Irradiation (505 nm, 50 mW / cm 2 , 5min) before and after DTNP cytotoxicity. (B) Light irradiation (505nm, 50mW / cm 2 ) Cytotoxicity at different time periods.
[0052] Fig.13 Photocontrolled DOX release from DOX / DTNP in retinoblastoma-bearing mice. (A) Representative IVIS fluorescence images of mice 1 h after DTNP injection. (B) Representative fluorescence images of mouse eyes 1 h after DOX / DTNP injection. (C) Fluorescence intensity of different tissues in mice 1 h after DOX / DTNP injection. Immediately after injection, light irradiation (505 nm, 50 mW / cm 2 , 5min).
[0053] Fig.14 Chemotherapy agents were injected intravenously in BALB / c nude mice bearing orthotopic WERI-Rb-1-GFP-luc tumors. For the irradiated group, agents were injected intravenously and then irradiated in the right eye of the mice (505 nm, 50 mW / cm 2 , 5min). (A) In vivo bioluminescence images of the eye. Photos were captured and analyzed using Live Imaging 4.5.2 software. For each group, images are shown on days 1, 7, 15, and 25 after treatment. (B) Tumor growth curves in each group. Data are shown as mean ± SD (n = 4). *p < 0.05. (C) Body weight changes (n = 4).
[0054] Fig.15 Representative photomicrographs of hematoxylin and eosin-stained sections of retina (with tumors), heart, lung, spleen, liver, and kidney from four groups (saline, free doxorubicin, DOX / DTNP, and DOX / DTNP+irradiation). Scale bar 50 μm.
[0055] Fig.16 The control group and the cells treated with DOX / DTNP and light irradiation (505 nm, 50 mW / cm 2 Representative photomicrographs of hematoxylin and eosin-stained sections of the retina of the group treated with 5 min × 5, 10 days. PhL, photoreceptor layer; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bar, 10 μm.
[0056] 5. Detailed description
[0057] Photoresponsive drug delivery systems (PDDS) can spatiotemporally control drug release, which is promising for biomedical applications. 1,2 However, the unreliable drug release process and poor light penetration depth in biological tissues remain challenging for further development of the system. 3 Here, we developed novel photocleavable three-legged small molecules (Scheme 1) that can self-assemble into nanocarriers to encapsulate hydrophobic drugs. 4,5Because the three-legged small molecule is the main structural unit of the nanocarrier, the cleavage of the three-legged molecule upon light irradiation can quickly lead to the decomposition of the nanocarrier, resulting in the rapid release of the drug only at the irradiated site. In addition, compared with conventional light-responsive drug delivery systems, this nanocarrier system can be triggered by green light irradiation, which has a deeper tissue penetration depth and lower phototoxicity than the commonly used UV light. 6 To demonstrate the potential applications of this system, the anticancer drug doxorubicin (DOX) was encapsulated in nanocarriers for the treatment of retinoblastoma (Scheme 1). A 505nm LED was used to trigger the release of DOX to kill cancer cells in the posterior segment of the eye. It should be noted that the nanocarriers can be administered intravenously for treatment, which can reduce the pain and side effects of conventional intravitreal injections. Green light penetrates deep enough to treat superficial diseases such as skin cancer and eye diseases. This is the first demonstration of light-triggered drug release for intravenous administration to treat retinoblastoma.
[0058] 6. Examples
[0059] Synthesis and Self-assembly of DTAEA Molecules
[0060] The photoresponsive three-legged molecule (DEAdcCM) 3-TAEA (DTAEA) was synthesized by coupling dicyanocoumarin (DEAdcCM) with the three amine groups of tris(2-aminoethyl)amine (TAEA). Figure 1 The synthetic route is shown, and its details are provided in the experimental section. Briefly, the commercially available 7-(diethylamino)-4-(hydroxymethyl)-coumarin (DEACM) photocage (compound 1) was modified with malononitrile to obtain dicyanocoumarin (DEAdcCM) (compound 4) as an intermediate. DEAdcCM was then linked to the amino group of TAEA via a nitrochloroformate-mediated reaction of the hydroxyl and amino groups. After purification by column chromatography, the product 1 H NMR ( 1 HNMR) Figure 2 ) and electrospray ionization-mass spectrometry (ESI-MS) ( Figure 3 ) confirmed the successful synthesis of DTAEA molecules. DEAdcCM showed broad UV-visible light absorption with two peaks at 480nm and 505nm, respectively. Compared with the UV-light-responsive DEACM photocage (absorption peak at 380nm), DEAdcCM has a red-shifted absorption of visible light in the blue-green range ( Figure 4 ), which would be more advantageous for biomedical applications.
[0061] The photoresponsive nanocarriers were constructed by nanoprecipitation. DTAEA can easily self-assemble into nanoparticles in aqueous solution. It is proposed that the π-π stacking interaction between DEAdcCM groups can promote the self-assembly process. 4,5During the self-assembly process, DSPE-mPEG 2000 Can be co-assembled with DTAEA for surface PEGylation ( Figure 5 a). Dynamic light scattering (DLS) analysis showed that the size of PEGylated DTAEA nanoparticles (abbreviated as DTNP) was about 90 nm with a narrow polydispersity (PDI) of 0.086 ( Figure 5 c). The morphology of DTNPs under transmission electron microscopy (TEM) showed well-dispersed nanoparticles with diameters of 70-100 nm ( Figure 5 b). In addition, the zeta potential of DTNP is about -27.0 mV ( Figure 5 d), due to the electrostatic repulsion between the negatively charged DTNPs, which will stabilize the nanoparticles and avoid aggregation. 8 To confirm the water stability, the size and PDI of DTNPs were monitored in PBS for a period of time. After incubation at 37 °C for 24 h, DTNPs remained stable and there was no significant change in size and PDI in PBS ( Figure 5 e).
[0062] Photocleavage and in vitro drug release
[0063] The photolysis mechanism of coumarin carbamate derivatives is reported as the formation of carbocations ( Figure 6 a). 9 To quantitatively determine the photolysis rate of free DTAEA, a quartz cuvette containing DTAEA in 50% acetonitrile / H2O was irradiated with 505 nm green LED light. At predetermined time points, the remaining DTAEA and the released DEAdcCM were determined by high performance liquid chromatography (HPLC). More than 90% of the DTAEA was released upon irradiation (505 nm, 50 mW / cm 2 ) for 1 min ( Figure 6 b), revealing the rapid photoresponse process of DTAEA. A similar photolysis process in DTAEA NPs took about 5 min to completely consume DTAEA ( Figure 6 c), which is slightly slower than free DTAEA in a mixture of acetonitrile and water. The hydrophobic environment of the nanoparticles that prevents nucleophilic attack of water molecules on the carbocation intermediates may be the reason for this result. Based on the photolysis performance of DTAEA and DTNP, the photolysis of the nanoparticles was performed with 50 mW / cm 2 The 505nm green LED light sets the irradiation duration to be no less than 5min.
[0064] Doxorubicin (DOX) has shown outstanding anticancer efficacy in the treatment of retinoblastoma. 10In this paper, we selected DOX as the cargo to be encapsulated into DTNPs. The UV-visible spectrum of DOX-loaded DTNPs (DOX / DTNPs) showed a broad absorption from 400 nm to 650 nm ( Figure 7 a), which covers the absorption area of DTAEA and DOX, demonstrating the successful encapsulation of DOX in DTNPs. Then, the loading capacity and encapsulation efficiency were optimized by feeding different ratios of DOX to DTAEA during the rapid nanoprecipitation process ( Figure 7 b). As the DOX to DTAEA ratio increased, the DOX loading increased from 3.0% (1:20DOX / DTAEA, w / w) to 36.0% (1:1DOX / DTAEA, w / w). Further increasing the DOX content resulted in a significant decrease in bulk aggregation and encapsulation efficiency, so we chose a 1:1 DOX to DTAEA ratio to prepare DOX / DTNPs in the following study. The encapsulation efficiency of DOX at this ratio was calculated to be 13.6%. In addition, the size and zeta potential of DOX / DTNPs did not change much compared to cargo-free DTNPs ( Figure 7 c), which suggests that drug loading does not affect the stability and surface properties of DTNPs.
[0065] The photoinduced decomposition of the nanocarriers was investigated by comparing TEM images of DTNPs before and after light irradiation. Figure 8 As shown, after exposure to green light (505nm, 50mW / cm 2 ) After 5 min, DTNP dissociated into smaller fragments, and no nanoparticles of the original size were observed. This light-triggered degradation of nanoparticles can lead to a burst release of the drug. To further evaluate the light-triggered drug release performance, the aqueous solution of DOX / DTNP was discontinuously irradiated with 505 nm light at intervals of 10 min. After each irradiation for 1 min, the solution was dialyzed with deionized water to separate the released drug for quantitative determination by HPLC. Fig. 9 As shown, the light-triggered release of doxorubicin exhibited an on-off pattern during intermittent irradiation. After 5 irradiations, the released DOX could reach about 60% of the encapsulated DOX. This result indicates that the dissociation of DTNP and the release of DOX can be controlled by 50 mW / cm 2 Precise control of low irradiance green LEDs.
[0066] Light-triggered cellular uptake of drugs
[0067] We further investigated the cellular uptake of photo-released DOX by fluorescence microscopy and flow cytometry. In this study, human umbilical vein endothelial cells (HUVEC) and human retinoblastoma cells (WERI-Rb-1) were used to investigate the cellular uptake. Cells were treated with various formulations including free DOX, DOX / DTNP, and DOX / DTNP + photoirradiation (hv). Fig.10 and Fig.11 As shown in (a), cells treated with DOX / DTNP and green light irradiation showed stronger fluorescence intensities in both the green channel (DEAdcCM) and the red channel (DOX) compared with cells without irradiation, indicating that the cellular uptake of DEAdcCM and DOX increased upon light irradiation. Fig.10 The red fluorescence intensity in cells incubated with free DOX was as high as that in the irradiated group, and both were much higher than that in the non-irradiated group. It is worth mentioning that DOX fluorescence was observed in the nuclei of both the free DOX group and the irradiated group, while the non-irradiated DOX / DTNP only showed cytoplasmic distribution, indicating that DOX was not released from DOX / DTNP without irradiation.
[0068] Flow cytometry was used to quantify the cellular uptake of DEAdcCM and released DOX. Fig.11 b, 11c, 11d) WERI-Rb-1 cells treated with DOX / DTNP+hv showed 4-fold higher DOX fluorescence intensity and 31.2-fold higher DEAdcCM fluorescence intensity than unirradiated cells, which showed the same trend as the results of fluorescence microscopy. In addition, the increased fluorescence intensity of DOX and DEAdcCM can be used as a clear signal for drug release monitoring and tumor imaging. In addition, the cytotoxicity of DTNP and the phototoxicity of green light irradiation to WERI-Rb-1 cells were studied by cell inhibition studies via MTT assay. We found that cargo-free DTNPs had no obvious cytotoxicity with or without irradiation in the concentration range of 1 to 200 μg / mL ( Fig.12 a). At 505nm and 50mW / cm 2 Green light irradiation under the condition of 30 min is harmless to cells. Fig.12 b).
[0069] All these results indicate that green light can trigger the release of DOX from DOX / DTNP, which increases the cellular uptake of the drug. In addition, the drug release process can be monitored based on the fluorescence of DEAdcCM and doxorubicin from incubated cells. DOX / DTNP can be used for application in in vivo targeted drug delivery with local irradiation at the diseased site.
[0070] Light-triggered intraocular drug accumulation
[0071] To verify that DOX / DTNP can achieve light-controlled drug delivery in vivo, an orthotopic retinoblastoma model was established to evaluate biodistribution and therapeutic efficacy. Typically, WERI-Rb-1 cells were slowly injected into the vitreous cavity of the right eye of Bulb / c nude mice for tumor transplantation. The tumor-bearing mice were further fed for one week and then injected intravenously with DOX / DTNP, followed by treatment with or without irradiation. The right eye was light-irradiated immediately after injection. Once irradiated after intravenous injection, the combined fluorescence of DEAdcCM and doxorubicin from DOX / DTNP could be observed in the right eye ( Fig.13 a), whereas the minimum fluorescence signal was found in the non-irradiated left eye of the irradiated group and in both eyes of the non-irradiated group.
[0072] To evaluate biodistribution, mice were euthanized after the above treatments, and their eyes (bilaterally), heart, lungs, liver, spleen, and kidneys were further removed for ex vivo fluorescence imaging. Higher fluorescence intensity was observed in the right eye of the irradiated group compared to the other groups (bilateral eyes of the untriggered group and the left eye of the triggered group) ( Fig.13 b). No significant differences were observed in heart, lung, liver, spleen and kidney between the groups with and without irradiation ( Fig.13 c), indicating that local eye irradiation cannot trigger drug release in other organs but only in the irradiated eye. This finding confirms our successful drug delivery to the eye bearing orthotopic tumors by light-controlled release of DOX from DTNPs. The photocleavage process is fast enough to achieve a burst release of drug at the irradiated site and lead to local drug accumulation. In addition, the nonspecific side effects of conventional chemotherapy will be almost eliminated because light irradiation does not trigger drug accumulation in other organs except the irradiated eye.
[0073] The therapeutic effect of photoreactive DOX / DTNP on retinoblastoma
[0074] In order to evaluate the in vivo therapeutic effect, WERI-Rb-1 cells were transfected with green fluorescent protein (GFP) and luciferase genes (abbreviated as WERI-Rb-1-GFP-luc) for in vivo tumor size monitoring. Seven days after intraocular injection of WERI-Rb-1-GFP-luc cells, the luminescent signal from the cells can be determined by the in vivo imaging system for in situ monitoring of in situ ocular tumors. Mice bearing WERI-Rb-1-GFP-luc orthotopic tumors were randomly divided into 4 groups and treated intravenously with saline, free DOX, DOX / DTNP, and DOX / DTNP+hv. The dosage was precisely controlled according to the weight of the mice and set to 5mg / kg body weight. The intravenous injection of the preparation was administered five times every two days. For the DOX / DTNP+hv group, after each intravenous injection of the preparation, green LED light (505nm, 50mW / cm 2) was irradiated in the right eye for 5 min. During the treatment, bioluminescence from the tumor was detected for tumor growth monitoring. Fig.14 As shown in a, eyes treated with DOX / DTNP and green light irradiation showed a much slower increase in tumor bioluminescence intensity than eyes treated with other formulations (saline, free DOX, DOX / DTNP without irradiation). Taking into account individual differences, tumor growth curves for different groups were obtained by setting the bioluminescence intensity on the day before treatment (day 0) as the starting point and determining the quantitative changes in subsequent days ( Fig.14 b). On day 15, the DOX / DTNP+HV group began to show significant effects in tumor suppression compared with the other preparations. On day 25, the increase in bioluminescence intensity in eyes treated with DOX / DTNP+HV (7.3-fold compared to day 0) was significantly lower than that in the saline group (104.5-fold compared to day 0), free DOX (64.0-fold compared to day 0), and DOX / DTNP (48.7-fold compared to day 0). It should be noted that two of the mice treated with DOX / DTNP+HV showed no bioluminescence signal on day 25, indicating that their tumors were completely eliminated. In addition, due to the severe side effects of chemotherapeutic drugs, the body weight of mice treated with free DOX ( Fig.14 c) decreased by about 10%. In the group treated with DOX / DTNP, no significant weight loss was observed during the treatment period, indicating no significant systemic toxicity for at least 25 days. The histological pattern of tumor-bearing retina and major organs was studied by hematoxylin and eosin (H&E) staining ( Fig.15 and Fig.16 ). Compared with the healthy retina, there were no histological changes in the retina after 25 days of treatment (DOX / DTNP+hv), indicating that DOX / DTNP and green light irradiation are safe for the retina under the treatment regimen. Except for the retina, the major organs did not show obvious necrosis at the end of the treatment, indicating that the intravenous injection of DOX / DTNP and the irradiation at the diseased eye have low systemic toxicity. Therefore, the intravenous injection of DOX / DTNP and the irradiation at the diseased eye achieve both high therapeutic efficacy and low systemic toxicity for retinoblastoma. Compared with free DOX, the low systemic toxicity of DOX / DTNP and irradiation is reasonably attributed to the extended circulation time of PEGylated nanoparticles and the less absorption in the liver and spleen. The rapid DOX release triggered by low irradiance green LED light promotes the accumulation of drugs in the posterior segment of the eye, where the drugs can play their role in treating retinoblastoma.
[0075] In summary, we developed a photocleavable three-legged molecule DTAEA, which can self-assemble into light-responsive nanocarriers. As an example, the hydrophobic drug DOX was encapsulated into the nanocarriers to achieve light-controlled drug delivery. Light irradiation triggered DOX release in mice bearing orthotopic retinoblastoma and achieved good anticancer efficacy. In addition to ocular diseases, this light-responsive drug delivery system can be applied to other diseases where light can reach the diseased site.
[0076] Synthesis of (DEAdcCM)3-TAEA three-legged molecule:
[0077] Compound 2: 7-Diethylamino-4-hydroxymethylcoumarin (DEACM, compound 1) (300 mg, 1.2 mmol) was dissolved in anhydrous dichloromethane (DCM) (20 mL) in a double flask. Acetic acid (83 μL, 1.44 mmol, 1.2 equiv) and 4-(dimethylamino)pyridine (DMAP) (180 mg, 1.44 mmol, 1.2 equiv) were then added to the DEACM solution. The mixture was cooled to 0 ° C and protected with nitrogen. 1,3-Dicyclohexylcarbodiimide (300 mg, 1.44 mmol, 1.2 equiv) was slowly added to the above solution. After stirring at 0 ° C for 10 minutes, the mixture was warmed to room temperature and stirred in the dark for 12 hours. The mixture was then diluted ten times with DCM and washed three times with 1.2 M hydrochloric acid and saturated sodium bicarbonate aqueous solution, respectively. The organic layer was collected, dried over sodium sulfate, and concentrated in vacuo. The residue was purified on a chromatography column using 20:1 DCM / MeOH (v / v) to give compound 2 as a yellow powder (yield: 311 mg, 88.6%).
[0078] Compound 3: Compound 2 (311 mg, 1.1 mmol) and Lawesson's reagent (285 mg, 0.68 mmol, 0.62 equiv) were dissolved in anhydrous toluene (40 mL) and protected with nitrogen in the dark. The mixture was heated to 115° C. and refluxed for 12 hours. The solvent was removed by rotary evaporation, and the residue was directly loaded into a silica column. The product was eluted with dichloromethane to obtain an orange-yellow powder as the product (yield: 220 mg, 77.6%).
[0079] Compound 4: Compound 3 (175 mg, 0.57 mmol) and malononitrile (52 mg, 0.91 mmol) were dissolved in 4 mL of acetonitrile (ACN). The mixture was added to triethylamine (0.3 mL) and stirred in the dark at room temperature for 2 hours. The complete consumption of compound 2 was confirmed using thin layer chromatography. AgNO3 (221.8 mg, 1.3 mmol) was then added and stirred for 2 hours. After filtering, the solvent was removed by rotary evaporation. The residue was purified on a chromatographic column using 1: 1 hexene / DCM (v / v) to obtain compound 4 as an orange-red powder (yield: 140 mg, 72.4%).
[0080] Compound 5: Compound 4 (140 mg, 0.41 mmol) was dissolved in anhydrous ethanol (50 mL) and aqueous HCl (37%, 33.6 mL, 0.4 mol) was slowly added. The resulting mixture was refluxed at 85 ° C for 16 hours in the dark under nitrogen. The solvent was removed under reduced pressure and purified on a chromatographic column using DCM to obtain compound 5 as an orange powder (yield: 108 mg, 88.2%).
[0081] Compound 6: Compound 5 (108 mg, 0.37 mmol) was dissolved in 10 mL of anhydrous DCM. N, N-diisopropylethylamine (DIPEA, 0.71 mL, 4.1 mmol) was added and the mixture was cooled to 0 ° C in the dark. After stirring for 15 minutes, a solution of 5 mL of anhydrous DCM of 4-nitrophenyl chloroformate (0.83 g, 4.1 mmol) was added dropwise to the above solution. The resulting mixture was warmed to room temperature and stirred for 6 hours. The mixture was washed with 0.01 M HCl aqueous solution (100 mL × 2). The organic layer was collected and evaporated under reduced pressure. The residue was purified on a chromatographic column using 20: 1 DCM / ethyl acetate (v / v) to obtain compound 6 as a red powder (yield: 153 mg, 90.8%).
[0082] Compound 7 (DTAEA): Compound 6 (153 mg, 0.33 mmol) was dissolved in 1.5 mL of anhydrous DCM under nitrogen and cooled to 0 ° C. DIPEA (105 μL, 0.6 mmol) was added and stirred for 15 minutes. A solution of tris (2-aminoethyl) amine (TAEA, 15 μL, 0.1 mmol) in 1 mL of anhydrous DCM was slowly added to the aforementioned solution at 0 ° C. The resulting mixture was allowed to warm to room temperature. After stirring for about 1 hour, a small amount of precipitation was observed. Then, more DIPEA (105 μL, 0.6 mmol) was added and the mixture was stirred overnight. The complete consumption of compound 6 was confirmed using thin layer chromatography. The residue was then evaporated under reduced pressure and loaded onto a chromatographic column. The final product was eluted using DCM / MeOH (0% to 4%) as an orange powder (yield: 78 mg, 63.4%).
[0083] References
[0084] [1] Yafei Li, Yaming Zhang, and Weiping Wang, Nano Research, 2018, 11(10), 5424 - 5438.
[0085] [2] Yanfei Wang, Chi - Hsiu Liu, Tianjiao Ji, Manisha Mehta, Weiping Wang, Elizabeth Marino, Jing Chen and Daniel S. Kohane, Nature Comm., 2019, 10, 804.
[0086] [3] S. Stolik, J. A. Delgado, A. Perez and L. Anasagasti, Journal of Photochemistry and Photobiology B: Biology, 2000, 57 90 - 93.
[0087] [4] Weiping Wang and Ying Chau, Chem. Commun., 2011, 47(37), 10224–10226.
[0088] [5] Weiping Wang and Ying Chau, Chem. Mater., 2012, 24(5), 946–953.
[0089] [6] Alina Y. Rwei, Weiping Wang, and Daniel S. Kohane, Nano Today, 2015, 10(4), 451–467.
[0090] [7] Shields Carol, Lally Sara, Leahey Ann, Jabbour Pascal, Caywood Emi, Schwendeman Rachela and Shields Jerry, Current Opinion in Ophthalmology, 2014, 25(5), 374 - 385.
[0091] [8]Albert Gandioso,Marta Palau,Alba Nin-Hill,Ivanna Melnyk,Carme Rovira,Santi Nonell,Dolores Velasco,Jaume García Amorós and Vicente Marchan,ChemistryOpen,2017,6,375-384.
[0092] [9]Ji-Young Kim, Jin-Ki Kim, Jeong-Sook Park, Youngro Byun and Chong-Kook Kim, Biomaterials, 2009, 30, 5751-5756.
[0093]
[10] Ruijuan Gao, Rajendra Narayan Mitra, Min Zheng, Kai Wang, Jesse Christine Dahringer, and Zongchao Han, Adv. Funct. Mater. 2018, 28, 1806248.
[0094] The above description of the specific embodiments will fully reveal the general nature of the present disclosure, so that others can easily modify such specific embodiments and / or adapt them to various applications by applying the knowledge in the relevant art technology (including the contents of the documents cited herein and incorporated herein by reference) without excessive experimentation, without departing from the overall concept of the present disclosure. Therefore, based on the teachings and guidance provided herein, such adaptations and modifications are intended to be within the meaning and scope of the equivalents of the disclosed embodiments. It should be understood that the wording or terminology herein is for the purpose of description rather than limitation, so that the terms or wording of this specification should be interpreted by those skilled in the art according to the teachings and guidance given herein and in combination with the knowledge of those skilled in the relevant art.
[0095] Although various embodiments of the present disclosure have been described above, it should be understood that they are provided by way of example and not limitation. It will be apparent to those skilled in the relevant art that various changes in form and detail may be made therein without departing from the spirit and scope of the present disclosure. Therefore, the present disclosure should not be limited by any of the above exemplary embodiments, but should only be limited according to the appended claims and their equivalents.
[0096] All references cited herein are incorporated by reference in their entirety and for all purposes to the same extent as if each individual publication or patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.
Claims
1. A drug delivery system comprising: A nanocarrier and an agent, wherein the nanocarrier comprises (DEAdcCM)3-TAEA (DTAEA) having the formula: The pharmaceutical agent is a hydrophobic drug.
2. The system of claim 1, wherein the nanocarrier has a size of 10-300 nm.
3. The system of claim 1 or 2, wherein the nanocarriers have a polydispersity coefficient of 0.4 to 0.
4. The system of claim 1 or 2, wherein the nanocarriers have a size of 90 nm and a polydispersity coefficient of 0.
086.
5. The system of claim 1 or 2, wherein the nanocarrier has a zeta potential of -10 mV to -40 mV.
6. The system of claim 1 or 2, wherein the nanocarrier has a zeta potential of -27 mV.
7. The system of claim 1 or 2, wherein the nanocarrier is photoresponsive.
8. The system of claim 1 or 2, wherein the agent is used for imaging or treatment of ocular diseases and other diseases where light can somehow reach its target.
9. The system of claim 8, wherein the ocular disease is selected from one or both of retinoblastoma and age-related macular degeneration.
10. The system of claim 8, wherein the certain manner is using optical fiber.
11. The system of claim 8, wherein the other diseases are selected from one or more of melanoma, subcutaneous tumor, esophageal cancer and gastric cancer.
12. The system of claim 1, wherein the agent is doxorubicin, paclitaxel, or capecitabine.
13. Use of a delivery system as claimed in any one of claims 1 to 12 in the preparation of a medicament for treating a disease in a subject, wherein the delivery system is administered to the subject, and the subject is irradiated with light.
14. The use according to claim 13, wherein the light is delivered by an LED light source, a lamp, a laser source or an optical fiber.
15. The use according to claim 13 or 14, wherein the nanocarrier is triggered by green light irradiation.
16. The use according to claim 13 or 14, wherein the light has a wavelength of 400-600 nm.
17. The use according to claim 13 or 14, wherein the light is a light having a wavelength of 505 nm and a power of 50 mW / cm 2 Green LED light lasts for 5 minutes.
18. The use of claim 13 or 14, wherein the delivery system is administered intravenously.
19. The use of claim 13 or 14, wherein the subject is irradiated 0-4 h after administration of the delivery system.
20. The use according to claim 13 or 14, wherein the disease is skin cancer, esophageal cancer, gastric cancer, eye diseases, retinoblastoma and other diseases in which light can reach its target.
21. A method of preparing the system of any one of claims 1-12, wherein DTAEA is assembled in the presence of DSPE-mPEG to form the nanocarrier.
22. A method for synthesizing (DEAdcCM)3-TAEA (DTAEA), the method comprising the steps of:
23. A method for synthesizing (DEAdcCM)3-TAEA (DTAEA), the method comprising the steps of: (i) The 7-(diethylamino)-4-(hydroxymethyl)-coumarin (DEACM) photocage having the following structure was modified with malononitrile To form dicyanocoumarin (DEAdcCM) having the following structure: (ii) DEAdcCM was linked to the TAEA amino group via a 4-nitrophenyl chloroformate-mediated reaction of the hydroxyl and amino groups to form DTAEA.
